Samsung Biologics secures 87.8% of PolyPeptide Group in tender offer

Samsung Biologics is closing in on its acquisition of Swiss CDMO PolyPeptide Group: 29.01 million shares, or 87.88% of the target stake, were tendered between September 15 and October 12, well above the 66.7% threshold. The offer price is CHF 44.31 per share, valuing the deal at CHF 1.46 billion (about KRW 2.7 trillion), the largest in Korean pharma history. Closing is expected by late November after regulatory approvals.

• 29.01 million shares tendered — 87.88% of target stake vs 66.7% threshold
• Offer price set at CHF 44.31 per share
• Deal value at CHF 1.46 billion (about KRW 2.7 trillion)
• Additional acceptance period runs October 19–30